Belpointe Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Belpointe Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-429	Closed	-$46K	–	771
2023 Q1	$46K	Buy	429 +56	+15%	+$6.41K	﹤0.01%	1750
2022 Q4	$45.6K	Buy	+373	New	+$43.3K	﹤0.01%	1668

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Belpointe Asset Management's ASND Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 429 shares — an estimated $46K sold.

Belpointe Asset Management first reported a position in ASND in Q4 2022 and held it in 2 quarters. The position peaked at $46K in Q1 2023. 158 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Belpointe Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 429 Ascendis Pharma A/S shares in Q2 2023, an estimated $46K.
Belpointe Asset Management first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Ascendis Pharma A/S position peaked at $46K in Q1 2023.
158 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.